Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose antithymocyte globulin to prevent GVHD after HLA-identical sibling HSCT
ChiCTR2000035017Phase 4Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of antithymocyte globulin in hematopoietic malignancies, Acute Leukaemia, chronic myelogenous leukemia (CML) and 1 more, sponsored by Sun Yat-sen University. Primary endpoint: Incidence of chronic graft-versus-host disease. Started Jul 2020; status: recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
hematopoietic malignanciesAcute Leukaemiachronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2000035017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035017.